Daily Updates
Lilly’s Next Obesity Drug Just Matched Bariatric Surgery in a Phase 3 Trial
Retatrutide is the most effective weight-loss drug ever tested in a Phase 3 trial. Eli Lilly reported positive topline results from the TRIUMPH-1 trial on
Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Retatrutide is the most effective weight-loss drug ever tested in a Phase 3 trial. Eli Lilly reported positive topline results from the TRIUMPH-1 trial on
The FDA is now operating with acting leaders in every senior position that matters for drug and biologics review. Within days of Commissioner Makary’s May
Merck’s sac-TMT Phase 3 win is the most important ADC data point since Enhertu’s early breast cancer approval last week. Sacituzumab tirumotecan, an antibody-drug conjugate
The World Health Organization declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern on
Three stories from the weekend reshape their respective markets. The Supreme Court ruled to maintain mifepristone access while litigation continues, resolving the near-term regulatory uncertainty
The Iran war’s impact on pharmaceutical supply chains is no longer theoretical. Evonik, a major supplier of pharma-grade amino and keto acids, announced a 15%
It’s over. FDA Commissioner Marty Makary resigned on Tuesday after 13 months in the role. The resignation followed days of reporting that the White House
Three deals worth a combined $19.5 billion were announced in a single day. Bristol Myers Squibb formed the largest China-to-West licensing partnership in biopharma history,
Daiichi Sankyo’s five-year plan is the most ambitious oncology roadmap any Japanese pharma company has ever published. The company is betting everything on antibody-drug conjugates,
This is the most consequential FDA leadership story since Makary took office. On Friday afternoon, the Wall Street Journal reported that President Trump was planning